Experienced in Mononucleosis

Dr. Jakub Svoboda

Oncology | Hematology Oncology | Hematology
University Of Penn-Medical Group
3400 Civic Ctr Blvd, 
Philadelphia, PA 
Offers Telehealth
Experienced in Mononucleosis
University Of Penn-Medical Group
3400 Civic Ctr Blvd, 
Philadelphia, PA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jakub Svoboda is an Oncologist and a Hematologist Oncology provider in Philadelphia, Pennsylvania. Dr. Svoboda is rated as an Experienced provider by MediFind in the treatment of Mononucleosis. His top areas of expertise are Non-Hodgkin Lymphoma, Hodgkin Lymphoma, B-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 149 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Mononucleosis.

Specialties
Oncology
Hematology Oncology
Hematology
Licenses
Internal Medicine in PA
Hospital Affiliations
Hospital Of Univ Of Pennsylvania
Chester County Hospital
Pennsylvania Hospital
Penn Presbyterian Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Avalon Health Care
  • MEDICARE PDP
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Geisinger
  • HMO
  • POS
  • PPO
Health Partners Plans
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

UNIVERSITY OF PENN-MEDICAL GROUP
3400 Civic Ctr Blvd, Philadelphia, PA 19104

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Phase II Trial of PET-Directed Therapy Using AVD (Doxorubicin, Vinblastine, and Dacarbazine) Plus Brentuximab Vedotin Induction Chemotherapy, With or Without Brentuximab Vedotin Plus Nivolumab, Followed by Nivolumab Consolidation for Patients With Previously Untreated Non-Bulky Limited Stage Hodgkin Lymphoma
A Phase II Trial of PET-Directed Therapy Using AVD (Doxorubicin, Vinblastine, and Dacarbazine) Plus Brentuximab Vedotin Induction Chemotherapy, With or Without Brentuximab Vedotin Plus Nivolumab, Followed by Nivolumab Consolidation for Patients With Previously Untreated Non-Bulky Limited Stage Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: October 03, 2025
Intervention Type: Drug, Biological, Other
Study Drugs: Brentuximab, Dacarbazine, Doxorubicin, Nivolumab, Vinblastine
Study Phase: Phase 2
A Phase I Study With an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients With Relapsed/Refractory Hodgkin Lymphoma
A Phase I Study With an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients With Relapsed/Refractory Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Brentuximab, Ipilimumab, Nivolumab
Study Phase: Phase 1/Phase 2
A Phase 2 Front-Line PET/CT-2 Response-Adapted Brentuximab Vedotin and Nivolumab Incorporated and Radiation-Free Management of Early Stage Classical Hodgkin Lymphoma (cHL)
A Phase 2 Front-Line PET/CT-2 Response-Adapted Brentuximab Vedotin and Nivolumab Incorporated and Radiation-Free Management of Early Stage Classical Hodgkin Lymphoma (cHL)
Enrollment Status: Active_not_recruiting
Publish Date: November 06, 2024
Intervention Type: Other, Drug, Biological
Study Drugs: Bleomycin, Brentuximab, Dacarbazine, Doxorubicin, Nivolumab, Vinblastine
Study Phase: Phase 2
Real World Observational Study Using clonoSEQ® Next Generation Sequencing in Hematologic Malignancies: The 'Watch' Registry
Real World Observational Study Using clonoSEQ® Next Generation Sequencing in Hematologic Malignancies: The 'Watch' Registry
Enrollment Status: Terminated
Publish Date: August 01, 2024
Intervention Type: Diagnostic test
Maintenance Lenalidomide Therapy After Autologous Stem Cell Transplant in Patients With High Risk Relapsed/Refractory Lymphomas
Maintenance Lenalidomide Therapy After Autologous Stem Cell Transplant in Patients With High Risk Relapsed/Refractory Lymphomas
Enrollment Status: Completed
Publish Date: March 27, 2023
Intervention Type: Drug
Study Drug: Lenalidomide
Study Phase: Phase 1/Phase 2
Phase Ib Study of Tisagenlecleucel in Combination With Pembrolizumab in Relapsed/Refractory (r/r) Diffuse Large B-cell Lymphoma (DLBCL) Patients.
Phase Ib Study of Tisagenlecleucel in Combination With Pembrolizumab in Relapsed/Refractory (r/r) Diffuse Large B-cell Lymphoma (DLBCL) Patients.
Enrollment Status: Completed
Publish Date: August 15, 2022
Intervention Type: Drug, Biological
Study Drugs: Tisagenlecleucel, Pembrolizumab
Study Phase: Phase 1
A Phase I/II Study Of Brentuximab Vedotin In Combination With Multi-Agent Chemotherapy As Front-Line Treatment In Patients With CD30 Positive Primary Mediastinal Large B-Cell, Diffuse Large B-Cell, And Grey Zone Lymphomas
A Phase I/II Study Of Brentuximab Vedotin In Combination With Multi-Agent Chemotherapy As Front-Line Treatment In Patients With CD30 Positive Primary Mediastinal Large B-Cell, Diffuse Large B-Cell, And Grey Zone Lymphomas
Enrollment Status: Completed
Publish Date: January 05, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1 Trial of SGN-CD70A in Patients With CD70-Positive Malignancies
A Phase 1 Trial of SGN-CD70A in Patients With CD70-Positive Malignancies
Enrollment Status: Completed
Publish Date: April 19, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 7 Less Clinical Trials

149 Total Publications

Enhanced CAR T-Cell Therapy for Relapsed Lymphoma. Reply.
Enhanced CAR T-Cell Therapy for Relapsed Lymphoma. Reply.
Journal: The New England journal of medicine
Published: August 06, 2025
Similar Doctors
Experienced in Mononucleosis
Dr. Pierluigi Porcu
Oncology | Hematology Oncology | Hematology
Experienced in Mononucleosis
Dr. Pierluigi Porcu
Oncology | Hematology Oncology | Hematology

Jefferson University Physicians

925 Chestnut St, Suite 3, 
Philadelphia, PA 
 (1.9 miles away)
215-955-8874
Languages Spoken:
English
See accepted insurances

Pierluigi Porcu is an Oncologist and a Hematologist Oncology provider in Philadelphia, Pennsylvania. Dr. Porcu is rated as an Elite provider by MediFind in the treatment of Mononucleosis. His top areas of expertise are T-Cell Lymphoma, Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides, Bone Marrow Transplant, and Bone Marrow Aspiration.

Experienced in Mononucleosis
Dr. Andrew M. Evens
Hematology | Hematology Oncology | Oncology
Experienced in Mononucleosis
Dr. Andrew M. Evens
Hematology | Hematology Oncology | Oncology

Rutgers Health-Rwj Scleroderma Program

1 Robert Wood Johnson Pl, 
New Brunswick, NJ 
 (54.5 miles away)
732-828-3000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Andrew Evens is a Hematologist and a Hematologist Oncology provider in New Brunswick, New Jersey. Dr. Evens is rated as an Elite provider by MediFind in the treatment of Mononucleosis. His top areas of expertise are Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Evens is currently accepting new patients.

Experienced in Mononucleosis
Dr. Usama S. Gergis
Hematology Oncology | Hematology | Oncology
Experienced in Mononucleosis
Dr. Usama S. Gergis
Hematology Oncology | Hematology | Oncology

Jefferson University Physicians

925 Chestnut St, Suite 3, 
Philadelphia, PA 
 (1.9 miles away)
215-955-8874
Languages Spoken:
English
See accepted insurances

Usama Gergis is a Hematologist Oncology specialist and a Hematologist in Philadelphia, Pennsylvania. Dr. Gergis is rated as a Distinguished provider by MediFind in the treatment of Mononucleosis. His top areas of expertise are Graft Versus Host Disease (GvHD), Acute Myeloid Leukemia (AML), Multiple Myeloma, Bone Marrow Transplant, and Bone Graft.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Svoboda's expertise for a condition
ConditionClose
View All 9 Elite Conditions
View All 9 Distinguished Conditions
View All 9 Advanced Conditions
View All 38 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile